Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination
Australian biotech Immutep has terminated a late-stage study evaluating its lead oncology candidate, eftilagimod alfa (efti), in combination with MSD’s…
Latest News
-
-
Parkinson’s research reaches “pivotal” stage, but barriers remain
Preclinical and clinical research focused on Parkinson’s disease has reached a “pivotal point”, but funding barriers and outdated clinical trial…
-
UK health authorities join forces to champion foreign infectious disease trials
Health divisions within the UK government and British non-profit organisations have banded together to support infectious disease trials in Africa,…
-
Pfizer’s trispecific heads to Phase III on mid-stage AD success
American pharmaceutical giant Pfizer is planning to take its trispecific antibody, tilrekimig, to Phase III in atopic dermatitis (AD) as…
-
Analysts tout market potential of Xenon’s epilepsy drug on Phase III win
Analysts have touted the market potential of Xenon Pharmaceuticals’ novel epilepsy drug, azetukalner, following a positive late-stage readout in patients…
-
Roche and Zealand’s Phase II obesity trial divides analyst opinion
Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial, but the…
-
FDA tells uniQure to conduct another study of Huntington’s gene therapy
uniQure's stock has dropped by more than 40% after being asked to conduct another study of its Huntington’s disease gene…
-
AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial
AtaiBeckley’s social anxiety disorder (SAD) drug has shown both safety and early signs of efficacy in a Phase IIa trial.…
-
ViiV’s four-monthly HIV drug maintains viral suppression at 12 months
ViiV Healthcare’s investigational four-monthly HIV drug maintains viral suppression at 12 months in a Phase IIb trial. In the EMBRACE…
-
EU clinical trial target could bring in additional €4bn funding
A further €4bn ($4.72bn) a year in funding could come into Europe if targets to increase clinical trials in the…
